In recent years, many clinical trials have also reported the efficacy of several novel EGFR TKIs and anti-EGFR monoclonal antibodies in NSCLC patients harboring EGFR ex20ins mutation, as shown in Table 1. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.